A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
← catalyst calendarNCT07165028 · readout ≤ 1,473 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
4,500estimated
Sites
564
Countries
Argentina, Australia, Austria +31
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-15 | actual | When the study began enrolling |
| Primary completion | Aug 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
- Drug: Tirzepatide — also filed as LY3298176
- Drug: Retatrutide — also filed as LY3437943
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes (MALO)
measured Baseline up to Study Completion (about 224 weeks)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed